MX2022014605A - Derivados de triptamina deuterada y metodos de uso. - Google Patents

Derivados de triptamina deuterada y metodos de uso.

Info

Publication number
MX2022014605A
MX2022014605A MX2022014605A MX2022014605A MX2022014605A MX 2022014605 A MX2022014605 A MX 2022014605A MX 2022014605 A MX2022014605 A MX 2022014605A MX 2022014605 A MX2022014605 A MX 2022014605A MX 2022014605 A MX2022014605 A MX 2022014605A
Authority
MX
Mexico
Prior art keywords
deuterated
methods
tryptamine derivatives
tryptamine
derivatives
Prior art date
Application number
MX2022014605A
Other languages
English (en)
Spanish (es)
Inventor
Alex Nivorozhkin
Michael Palfreyman
Original Assignee
Cybin Irl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cybin Irl Ltd filed Critical Cybin Irl Ltd
Priority claimed from PCT/IB2021/054340 external-priority patent/WO2021234608A1/en
Publication of MX2022014605A publication Critical patent/MX2022014605A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
MX2022014605A 2020-05-19 2021-05-19 Derivados de triptamina deuterada y metodos de uso. MX2022014605A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063026939P 2020-05-19 2020-05-19
US202063114738P 2020-11-17 2020-11-17
US202163157118P 2021-03-05 2021-03-05
PCT/IB2021/054340 WO2021234608A1 (en) 2020-05-19 2021-05-19 Deuterated tryptamine derivatives and methods of use

Publications (1)

Publication Number Publication Date
MX2022014605A true MX2022014605A (es) 2022-12-16

Family

ID=78608612

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014605A MX2022014605A (es) 2020-05-19 2021-05-19 Derivados de triptamina deuterada y metodos de uso.

Country Status (11)

Country Link
US (12) US12240813B2 (https=)
EP (2) EP4397371A3 (https=)
JP (4) JP7766623B2 (https=)
KR (2) KR20230012501A (https=)
CN (2) CN115667217A (https=)
AU (2) AU2021276656A1 (https=)
CA (1) CA3177454A1 (https=)
CO (1) CO2022016662A2 (https=)
IL (3) IL297492A (https=)
MX (1) MX2022014605A (https=)
PH (1) PH12022553135A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
CA3152752A1 (en) 2019-10-01 2021-04-08 Thomas Henley Genetic engineering of fungi to modulate tryptamine expression
KR20220082092A (ko) 2019-11-07 2022-06-16 스몰 파마 엘티디 화합물
BR112022015379A2 (pt) 2020-02-04 2022-09-27 Mindset Pharma Inc Derivados de 3-pirrolidino-indol como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc
KR20220137081A (ko) 2020-02-04 2022-10-11 마인드셋 파마 인크. Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체
WO2021226416A1 (en) 2020-05-08 2021-11-11 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
US11324762B2 (en) 2020-10-08 2022-05-10 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof
US12521370B2 (en) 2020-12-01 2026-01-13 Cybin Uk Ltd Inhalable formulations
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
AU2022229037A1 (en) * 2021-03-02 2023-09-28 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
WO2022235500A1 (en) * 2021-05-03 2022-11-10 Mind Medicine, Inc. Psychedelics for treatment of pain
CA3218110A1 (en) 2021-05-25 2022-12-01 Majed Fawaz New n,n-dimethyltryptamine salts and crystalline salt forms
AU2022287974A1 (en) 2021-06-09 2024-01-04 Atai Therapeutics, Inc. Novel prodrugs and conjugates of dimethyltryptamine
US11344564B1 (en) 2021-08-20 2022-05-31 Lennham Pharmaceuticals, Inc. Method of treatment based on reduced monoamine oxidase a activity
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
US12318477B2 (en) 2021-11-18 2025-06-03 Cybin Uk Ltd Injectable and inhalable formulations
WO2023129956A2 (en) 2021-12-30 2023-07-06 ATAI Life Sciences AG Dimethyltryptamine analogues as nitric oxide delivery drugs
CN118984868A (zh) 2021-12-31 2024-11-19 恩派瑞安神经科学公司 用于产生精神药物生物碱的遗传修饰的生物体
EP4463440A1 (en) * 2022-01-14 2024-11-20 Cybin IRL Limited Tryptamine compositions and methods
KR20250053871A (ko) * 2022-08-31 2025-04-22 사이빈 아이알엘 리미티드 트립타민 화합물, 조성물, 및 사용 방법
AU2023361184A1 (en) 2022-10-13 2025-04-24 Cybin Uk Ltd Method of administration of a parenteral formulation comprising a psychedelic agent
WO2024108195A1 (en) 2022-11-17 2024-05-23 Remedi, Inc. Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use
CN121038789A (zh) 2023-01-23 2025-11-28 赛本英国有限公司 通过肠胃外施用单一有效肠胃外剂量的短效致幻剂治疗精神或神经障碍
CN121194779A (zh) * 2023-03-31 2025-12-23 赛本英国有限公司 包含单胺抗抑郁剂和短效致幻剂的组合
EP4704806A1 (en) * 2023-05-05 2026-03-11 Cybin IRL Limited Injectable pharmaceutical formulations
CN121752545A (zh) * 2023-11-06 2026-03-27 宜昌人福药业有限责任公司 一种n,n-二甲基色胺衍生物及其药物组合物、制备方法和用途

Family Cites Families (389)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE265636C (https=)
CA672478A (en) 1963-10-15 Heim Roger Psilocybin and psilocin
DE255749C (https=)
GB672478A (en) 1949-07-22 1952-05-21 Atlas Diesel Ab Method and means for connecting drill rods, drill steels or drill bits for rock drilling
GB912715A (en) 1958-02-21 1962-12-12 Sandoz Ltd 4-hydroxytryptamines
GB911946A (en) 1958-02-21 1962-12-05 Sandoz Ltd Psilocybin and psilocin and processes for their preparation
BE582353A (https=) 1958-09-12
US3072530A (en) 1958-09-12 1963-01-08 Sandoz Ag Therapeutic indoles for psychic stimulation and relief of mental depression
US3078214A (en) 1958-09-12 1963-02-19 Sandoz Ag Treatment of mental disturbances with esters of indoles
FI34529A (fi) 1959-01-28 1964-10-10 Sandoz Ag Förfarande att i rent tillstånd tillvarataga de psykotropiskt verksamma föreningarna psilocybin och psilocin ur svamparter
US3192111A (en) 1959-02-16 1965-06-29 Sandoz Ltd Method of inducing therapeutic tranquilization with psilocybin and psilocin
GB981192A (en) 1960-03-30 1965-01-20 Westminster Bank Ltd Improvements in or relating to 4 hydroxytryptamine esters
GB982738A (en) 1961-06-05 1965-02-10 Ici Ltd 3-aminoalkylindoles
US3444174A (en) 1966-10-05 1969-05-13 American Cyanamid Co Substituted 4,7-dihydroindoles
US3583972A (en) 1969-06-11 1971-06-08 Upjohn Co N-dealkylation of cyclic tertiary amines
US3686213A (en) 1970-08-28 1972-08-22 American Cyanamid Co Substituted aminoethyl indoles
JPS55105664A (en) 1979-02-08 1980-08-13 Kawaken Fine Chem Co Ltd Preparation of tryptamine
US4855325A (en) 1985-01-16 1989-08-08 Naftchi Nosrat E Treatment of mammals suffering from damage to the central nervous system
EP0152379A3 (de) 1984-02-15 1986-10-29 Ciba-Geigy Ag Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend unilamellare Liposomen
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US6107499A (en) 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
AU6170990A (en) 1989-08-11 1991-03-11 Malcolm H. Skolnick Method for chemical promotion of the effects of low current transcranial electrostimulation
US5158956A (en) 1990-05-04 1992-10-27 Eli Lilly And Company Method of inhibiting gastric acid secretion with benzodioxanes
US5340838A (en) 1990-05-04 1994-08-23 Eli Lilly And Company Method of inhibiting gastric acid secretion with 2-phenylcyclopropylamines
US5258379A (en) 1990-05-04 1993-11-02 Eli Lilly And Company Method of inhibiting gastric acid secretion with n-arylpiperazines
CS276073B6 (cs) 1990-08-14 1992-03-18 Mikrobiologicky Ustav Csav Způsob přípravy biomasy s obsahem psilocybinu a peilociau ze etopkovýtrusá houby
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
FR2707639B1 (fr) 1993-06-30 1995-10-13 Pf Medicament Nouveaux composés indoliques dérivés d'arylamines comme ligands sélectifs des récepteurs 5HT1D et 5HT1B.
US5417987A (en) 1993-09-16 1995-05-23 Board Of Supervisors Of Louisiana State University Method for controlling bivalves such as zebra mussels
JPH0827029A (ja) 1994-07-19 1996-01-30 Fujisawa Pharmaceut Co Ltd ５ｈｔ１ 作動薬の新規医薬用途
JPH0827020A (ja) 1994-07-19 1996-01-30 Mitsubishi Chem Corp 破骨細胞形成促進及び骨吸収剤
US6207396B1 (en) 1995-11-20 2001-03-27 Microgenics Corporation Immunoassay reagents and methods for determination of LSD and LSD metabolites
US6613508B1 (en) 1996-01-23 2003-09-02 Qiagen Genomics, Inc. Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques
DE69700902T2 (de) 1996-01-23 2000-07-20 Rapigene, Inc. Verfahren zur erkennung von ligandenpaar bindung mit erhöter empfindlichkeit
US6312893B1 (en) 1996-01-23 2001-11-06 Qiagen Genomics, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
EP0992511B1 (en) 1996-01-23 2009-03-11 Operon Biotechnologies, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
US6027890A (en) 1996-01-23 2000-02-22 Rapigene, Inc. Methods and compositions for enhancing sensitivity in the analysis of biological-based assays
DE69701671T3 (de) 1996-01-23 2006-08-17 Qiagen Genomics, Inc., Bothell Verfahren und zusammenstellungen zur sequenzbestimmung von nukleinsäuremolekülen
EP0962464A3 (en) 1996-01-23 2004-02-11 Qiagen Genomics, Inc. Methods and compositions for detecting binding of ligand pair using non-fluorescent label
FR2744361B1 (fr) 1996-02-07 1998-02-27 Rhone Poulenc Rorer Sa Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
CA2297158C (en) 1997-07-22 2009-12-22 Rapigene Inc. Methods and compounds for analyzing nucleic acids by mass spectrometry
AU2775299A (en) 1998-02-20 1999-09-06 Microgenics Corporation Immunoassays for determination of lsd and lsd metabolites
US6306616B1 (en) 1998-03-27 2001-10-23 Microgenics Corporation Adsorption type confirmatory assays
DE1066523T1 (de) 1998-03-27 2001-09-20 Microgenics Corp., Pleasanton Kontrollbestimmungsmethoden für drogen bestehend aus kleinen molekülen
AU3230299A (en) 1998-05-29 1999-12-09 Armacel Pty Limited An anchor mounting and installation method
AU4984899A (en) 1998-07-14 2000-02-07 Adams Food Ltd. Nutritionally active composition for hardening fingernails
MXPA01001180A (es) 1998-07-31 2002-04-24 Vela Pharmaceuticals Inc Metodos y composiciones para el tratamiento y la prevencion de abuso de sustancias empleando moclobemida.
US6376531B1 (en) 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
US20010008641A1 (en) 1998-11-25 2001-07-19 R. Douglas Krotzer Nutritionally active composition for bodybuilding
CA2353962C (en) 1998-12-11 2009-09-29 Virginia Commonwealth University Selective 5-ht6 receptor ligands
US6403808B1 (en) 1999-12-10 2002-06-11 Virginia Commonwealth University Selective 5-HT6 receptor ligands
EP1693366A1 (en) 1998-12-11 2006-08-23 Virginia Commonwealth University Selective 5-HT 6 receptor ligands
AU2001225664A1 (en) 2000-06-15 2001-12-24 Respiratorius Ab 5-ht3 receptor antagonists for treatment of disorders involving airway constriction
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
WO2002005849A2 (en) 2000-07-19 2002-01-24 Pitmy International N.V. Transportation of nucleic acid substances
EP1409530A2 (en) 2000-09-19 2004-04-21 Microbia, Inc. Modulation of secondary metabolite production by zinc binuclear cluster proteins
WO2002036114A1 (en) 2000-11-01 2002-05-10 Respiratorius Ab Composition comprising serotonin receptor antagonists, 5 ht-2 and 5 ht-3
AU2002212888A1 (en) 2000-11-01 2002-05-15 Respiratorius Ab Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
US20030096013A1 (en) 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
DK1859798T3 (en) 2001-03-29 2016-03-21 Lilly Co Eli N- (2-arylethyl) -BENZYLAMINER as antagonists of 5-HT6 receptor
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
WO2002102988A2 (en) 2001-06-18 2002-12-27 Psychiatric Genomics, Inc. Method for neural stem cell differentiation using 5ht-1a agonists
ITRM20010356A1 (it) 2001-06-21 2002-12-23 Sigma Tau Ind Farmaceuti "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
US20030007961A1 (en) 2001-06-22 2003-01-09 Wilburn Michael D. Orthomolecular vitamin E derivatives
US20030078231A1 (en) 2001-06-22 2003-04-24 Wilburn Michael D. Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties
WO2003016903A2 (de) 2001-08-20 2003-02-27 Walter Pils Vorrichtung und verfahren zum nachweis eines analyten
AT501069A1 (de) 2001-08-20 2006-06-15 Walter Ing Pils Vorrichtung und verfahren zum nachweis eines analyten
ATE496917T1 (de) 2001-12-20 2011-02-15 Randox Lab Ltd Haptene, immunogene, antikörper und konjugate für 2-oxo-3-hydroxy lsd
US20040258617A1 (en) 2002-06-17 2004-12-23 Pearl Technology Holdings, Llc. Physical, chemical, and isotopic (atomic) labels
DE60329607D1 (de) 2002-06-21 2009-11-19 Suven Life Sciences Ltd Sich als therapeutische mittel eignende arylalkylindole mit affinität für den serotoninrezeptor, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
DK1523486T3 (da) 2002-06-21 2008-03-03 Suven Life Sciences Ltd Tetracykliske arylsulfonylindoler med serotoninreceptor-affinitet
US11180781B2 (en) 2016-08-21 2021-11-23 Insectergy, Llc Biosynthetic cannabinoid production methods
US10738268B2 (en) 2016-08-21 2020-08-11 Insectergy, Llc Cannabis nanoemulsion methods
US7138252B2 (en) 2002-07-17 2006-11-21 Cytos Biotechnology Ag Molecular antigen arrays
CA2487849A1 (en) 2002-07-18 2004-01-29 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
WO2004054500A2 (en) 2002-08-05 2004-07-01 Baxter International Inc. Preparation of submicron sized particles with polymorph control and new polymorph of itraconazole
CN1688288A (zh) 2002-08-05 2005-10-26 巴克斯特国际公司 具有多晶型控制的亚微米粒度颗粒的制备和新多晶型伊曲康唑
AU2003278832A1 (en) 2002-09-13 2004-04-30 Carnegie Mellon University Optical biosensors and methods of use thereof
CN1703199B (zh) 2002-10-11 2010-04-28 伊迪亚股份公司 具有增强的可变形性、包含至少三种两亲性物质的聚集物,其用于改善通过半透屏障的转运以及非侵入性药物在体内、具体是通过皮肤的应用
US20040105881A1 (en) 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
WO2004111185A2 (en) 2002-10-30 2004-12-23 The Regents Of The University Of California Direct micro-patterning of lipid bilayers using uv light and selected uses thereof
JP4174016B2 (ja) 2003-07-11 2008-10-29 株式会社ビーエル 競合法によるサイロシン類のイムノクロマトグラフィー検出法及びテストキット
JP4641942B2 (ja) 2003-10-03 2011-03-02 フェーイレン・ナムローゼ・フェンノートシャップ ヒトおよび動物におけるｉｇｆ−１血清レベルの低下と関連した種々の疾患状態の治療用の治療用組成物の製造のための血清中ｉｇｆ−１レベルを増加できる化合物の使用
US20050288616A1 (en) 2004-06-28 2005-12-29 Smiths Detection, Inc. Sampling swab
US7783333B2 (en) 2004-07-13 2010-08-24 Dexcom, Inc. Transcutaneous medical device with variable stiffness
US7655691B2 (en) 2004-09-27 2010-02-02 Sard Howard P Indole compounds useful as serotonin selective agents
US20060192098A1 (en) 2005-01-10 2006-08-31 Smiths Detection Inc. Sampling swab
DE102005008312A1 (de) 2005-02-17 2006-08-24 Birds Pharma Gmbh Berolina Innovative Research & Development Services Verwendung deuterierter N-[2-(5-Methoxy-1H-indol-3-yl)-ethyl]acatamide und deren pharmazeutisch verträglicher Salze sowie diese Verbindungen enthaltende Arzneimittel
WO2007024741A2 (en) 2005-08-24 2007-03-01 National Jewish Medical And Research Center Methods for treatment of thiol-containing compound deficient conditions
PT1954669E (pt) 2005-12-01 2015-10-23 Auspex Pharmaceuticals Inc Feniletilaminas substituídas com actividade serotoninérgica e/ou norepinefrinérgica
US20080101995A1 (en) 2005-12-16 2008-05-01 Smiths Detection Inc. Ion mobility spectrometer having improved sample receiving device
US20090028796A1 (en) 2006-01-30 2009-01-29 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. Pesticidal composition comprising indole derivates
CA2640502A1 (en) 2006-01-30 2007-08-02 Max-Planck Gesellschaft Zur Foerderung Der Wissenschaften E.V. Pesticidal composition comprising indole derivates
FI3756537T3 (fi) 2006-02-22 2023-10-10 Dexcom Inc Analyyttianturi
GB0604647D0 (en) 2006-03-08 2006-04-19 Shchepinov Mikhail Stabilized food supplements and their derivatives
GB0606147D0 (en) 2006-03-28 2006-05-10 Bioniqs Ltd Method
WO2008003028A2 (en) 2006-06-28 2008-01-03 Chelsea Therapeutics, Inc. Pharmaceutical compositions comprising droxidopa
US20080010318A1 (en) 2006-07-05 2008-01-10 Samsung Electronics Co., Ltd. Apparatus and method for managing content stored in portable digital device
WO2008016677A2 (en) 2006-08-02 2008-02-07 Auspex Pharmaceuticals, Inc. Preparation and utility of deuterated amphetamines
DE102006040027B3 (de) 2006-08-25 2008-06-26 Christian Beer Vakuumförderer zum Transport, Ablegen und Stapeln von flächenförmigen Gegenständen
CA2666149A1 (en) 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
US8653106B2 (en) 2010-07-30 2014-02-18 Pisgah Laboratories, Inc. Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder
US20120183600A1 (en) 2007-01-16 2012-07-19 Chien-Hung Chen Novel composition for treating metabolic syndrome and other conditions
ES2500053T3 (es) 2007-03-09 2014-09-29 Chelsea Therapeutics, Inc. Composición farmacéutica que comprende droxidopa para el tratamiento de la fibromialgia
WO2008112773A2 (en) 2007-03-12 2008-09-18 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension
SI2125698T1 (sl) 2007-03-15 2016-12-30 Auspex Pharmaceuticals, Inc. Devterirani d9-venlafaksin
CN102014995B (zh) 2007-03-30 2015-05-13 菲利普莫里斯生产公司 用于输送药剂的装置和方法
WO2008122990A1 (en) 2007-04-04 2008-10-16 Almet Corporation Limited Compacting upflow extractor and method of using it
EP2062903A1 (en) 2007-04-18 2009-05-27 Teva Pharmaceutical Industries Ltd. Statin intermediates and process for the preparation of statins
JP2010526820A (ja) 2007-05-07 2010-08-05 チェルシー・セラピューティクス，インコーポレイテッド 気分障害、睡眠障害、または注意欠陥障害を治療するドロキシドパおよびその医薬組成物
US10183001B1 (en) 2007-05-22 2019-01-22 Pisgah Laboratories, Inc. Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features
US9421266B2 (en) 2007-05-22 2016-08-23 Pisgah Laboratories, Inc. Safety of pseudoephedrine drug products
US7745665B2 (en) 2007-06-04 2010-06-29 Auspex Pharmaceuticals, Inc. Substituted phenethylamines
NO326090B1 (no) 2007-06-18 2008-09-15 Ziebel As Hylseventil
ES2358288T3 (es) 2007-08-01 2011-05-09 Laboratorios Del Dr. Esteve S.A. Combinación de al menos dos ligandos de 5ht6.
AU2016208412A1 (en) 2007-08-06 2016-08-18 Biotie Therapies, Inc. Methods for treating dependence
AU2014202047A1 (en) 2007-08-06 2014-05-01 Biotie Therapies, Inc. Methods for treating dependence
EP3251670A1 (en) 2007-08-06 2017-12-06 Biotie Therapies, Inc. Methods for treating dependence
US20090043184A1 (en) 2007-08-08 2009-02-12 Edwards Lifesciences Corporation Catheter and probe for measuring analytes or other parameters
JP2010540454A (ja) 2007-09-21 2010-12-24 アカディア ファーマシューティカルズ，インコーポレーテッド ピマバンセリンと他の薬剤との併用投与
EP2209380A4 (en) 2007-10-09 2011-09-14 Mark T Hamann METHOD OF USE OF COMPOSITIONS WITH ANTIDEPRESSIVE EFFICACY, MOOD EFFICACY AND OTHER NEUROLOGICAL EFFECTIVENESS AND COMPOSITIONS THEREOF
EP3090743A1 (en) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
WO2009097596A1 (en) 2008-01-31 2009-08-06 Paul Griffin Compositions and methods for the treatment of chronic infections
US8329663B2 (en) 2008-01-31 2012-12-11 Paul Griffin Compositions and methods for the treatment of chronic infections
AU2009214724A1 (en) 2008-02-11 2009-08-20 Organix Inc. Indole compounds and methods of use thereof
EP2280703A1 (en) 2008-03-12 2011-02-09 Københavns Universitet (University Of Copenhagen) Use of npy y5 receptor antagonists for the prevention of psychostimulant and opioid abuse
CA2666036C (en) 2008-05-16 2017-09-12 Chien-Hung Chen Novel compositions and methods for treating hyperproliferative diseases
EP2285362B1 (en) 2008-06-19 2017-08-09 LTS LOHMANN Therapie-Systeme AG Composition for transdermal delivery of cationic active agents
CA2732823A1 (en) 2008-08-13 2010-02-18 George Mason Intellectual Properties, Inc. Ex vivo therapeutic screening of living bone marrow cells for multiple myeloma
EP4549933A3 (en) 2008-09-19 2025-05-21 DexCom, Inc. Particle-containing membrane and particulate electrode for analyte sensors
WO2010088911A1 (en) 2009-02-06 2010-08-12 Egalet A/S Pharmaceutical compositions resistant to abuse
JP5550839B2 (ja) 2009-02-09 2014-07-16 株式会社 資生堂 美白剤
NZ619408A (en) 2009-03-11 2015-08-28 Omeros Corp Compositions and methods for prophylaxis and treatment of addictions
EP2419400A1 (en) 2009-04-15 2012-02-22 Research Triangle Institute Monoamine reuptake inhibitors
WO2010124089A2 (en) 2009-04-22 2010-10-28 Synosia Therapeutics, Inc. Methods for treating dependence
WO2010151258A1 (en) 2009-06-24 2010-12-29 The Board Of Regents Of The University Of Oklahoma Methods of treating psychological conditions
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
EP2473199A1 (en) 2009-08-31 2012-07-11 Brain Watch Ltd. Isotopically labeled neurochemical agents and uses thereof for diagnosing conditions and disorders
WO2011028875A1 (en) 2009-09-03 2011-03-10 Wake Forest University Health Sciences Immunogenic conjugates for producing immune responses to drugs of abuse and methods of use
IN2012DN02325A (https=) 2009-09-16 2015-08-21 Philip Morris Products Sa
EP2482724A2 (en) 2009-09-30 2012-08-08 Dexcom, Inc. Transcutaneous analyte sensor
CN102115455A (zh) 2009-12-30 2011-07-06 北京德众万全药物技术开发有限公司 一种赛洛多辛关键中间体的制备方法
AU2011250962B2 (en) 2010-05-10 2015-09-03 Gfbiochemicals Limited Personal care formulations containing alkyl ketal esters and methods of manufacture
WO2011140608A1 (en) 2010-05-14 2011-11-17 Keating Charlotte L Neuropsychopharmacological treatment regimes for treating psychological disorders
AU2011252763B2 (en) 2010-05-14 2012-12-20 Charlotte L. Keating A method of treatment and diagnosis
US20120108510A1 (en) 2010-05-20 2012-05-03 Emory University Methods of improving behavioral therapies
US20110319728A1 (en) 2010-06-29 2011-12-29 Edwards Lifesciences Corporation Blood parameter sensor and flow control system, method and computer program product
WO2012074588A2 (en) 2010-08-30 2012-06-07 President And Fellows Of Harvard College Shear controlled release for stenotic lesions and thrombolytic therapies
CA2816595C (en) 2010-10-07 2018-11-27 Eaglepharma Pty Ltd Combination therapy for the treatment of depression and other non-infectious diseases
EP2632334B1 (en) 2010-10-27 2020-09-09 Dexcom, Inc. Continuous analyte monitor data recording device operable in a blinded mode
CA2816551A1 (en) 2010-11-03 2012-05-10 Mcmaster University Method of treating mucosal inflammation
EP3834869B1 (en) 2010-12-22 2024-06-05 Syqe Medical Ltd. System for drug delivery
CA2824900A1 (en) 2011-01-18 2012-07-26 Targacept, Inc. Treatment of cognitive dysfunction in schizophrenia
CN103502817B (zh) 2011-03-28 2016-01-20 前视红外系统股份有限公司 包括药物的分析物的检测方法
WO2012139042A2 (en) 2011-04-08 2012-10-11 Dexcom, Inc. Systems and methods for processing and transmitting sensor data
EP2720536A4 (en) 2011-06-16 2015-04-01 Harvard College NEW AGENTS FOR COMBATING NAILS AND APPLICATIONS THEREOF
EP2551675A1 (en) 2011-07-28 2013-01-30 Chiron AS Deuterium free, stable isotope labeled 2-phenylethylamine hallucinogens and/or stimulants, methods fo their preparation and their use
US10349871B2 (en) 2011-08-05 2019-07-16 Dexcom, Inc. Systems and methods for detecting glucose level data patterns
US9549692B2 (en) 2011-08-26 2017-01-24 Dexcom, Inc. Polymer membranes for continuous analyte sensors
EP4465307A3 (en) 2011-09-23 2025-02-19 Dexcom, Inc. Systems and methods for processing and transmitting sensor data
WO2013064690A1 (de) 2011-11-04 2013-05-10 Chv Pharma Gmbh & Co. Kg Inhalator sowie verfahren zum erzeugen eines aerosols
US10398379B2 (en) 2011-12-15 2019-09-03 Becton, Dickinson And Company System for improved interpretation of physiological data and presentation of physiological condition management information
GB201202223D0 (en) 2012-02-09 2012-03-28 Randox Lab Ltd Immunoassay for pyrrolidinophenones
CN104508126B (zh) 2012-03-23 2017-06-30 科德克希思公司 用于合成色胺和色胺类似物的衍生物的生物催化剂和方法
US10881339B2 (en) 2012-06-29 2021-01-05 Dexcom, Inc. Use of sensor redundancy to detect sensor failures
US8986677B2 (en) 2012-07-30 2015-03-24 Pop Test Cortisol Llc Therapeutic compositions and methods
EP2882474A4 (en) 2012-08-08 2016-05-11 Presage Biosciences Inc EXTRUSION METHODS AND DEVICES FOR ACTIVE INGREDIENT RELIEF
US20140066881A1 (en) 2012-08-31 2014-03-06 Zoll Medical Corporation Cardiac resuscitation methods and kits
US20150231300A1 (en) 2012-10-28 2015-08-20 Peritech Pharma Ltd. Pharmaceutical liquid adhesive compositions for treatment of anorectal disorders
EP2914174A4 (en) 2012-10-31 2016-07-06 Edwards Lifesciences Corp SENSOR SYSTEMS AND METHOD FOR USE THEREOF
US20140170146A1 (en) 2012-11-13 2014-06-19 Presage Biosciences, Inc. Methods for multiplexed drug evaluation
US20140242722A1 (en) 2013-02-27 2014-08-28 Medtech Detect, Llc Article and method for detection of a drug in a liquid medium
WO2014140925A2 (en) 2013-03-10 2014-09-18 Peritech Pharma Ltd. Topical compositions and methods of treatment of topical disorders
US9561183B2 (en) 2013-03-15 2017-02-07 Children's National Medical Center Prussian blue-inspired constructs for multimodal imaging and therapy
WO2014144130A2 (en) 2013-03-15 2014-09-18 Als Mountain Llc Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof
US8999992B2 (en) 2013-03-15 2015-04-07 Vm Pharma Llc Crystalline forms of tryosine kinase inhibitors and their salts
CA2906765A1 (en) 2013-03-15 2014-09-18 Biochemics, Inc. Topical formulations and methods for drug delivery
WO2014152182A1 (en) 2013-03-15 2014-09-25 President And Fellows Of Harvard College Deuterated heterocyclic inhibitors of necroptosis
UA116796C2 (uk) 2013-03-15 2018-05-10 Філіп Морріс Продактс С.А. Система, що генерує аерозоль, з диференціальним нагріванням
AU2014270525B2 (en) 2013-05-21 2018-06-14 Philip Morris Products S.A. Aerosol comprising distributing agent and a medicament source
PL2999365T3 (pl) 2013-05-21 2021-04-19 Philip Morris Products S.A. Układ dostarczania aerozolu z grzaniem elektrycznym
CA2927000A1 (en) 2013-10-09 2015-04-16 Georgia-Pacific Chemicals Llc Collector compositions and methods for making and using same
KR101629502B1 (ko) 2013-10-23 2016-06-10 주식회사 엘지생활건강 세정효과가 우수한 저자극 클렌징 워터 화장료 조성물
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
TW201605856A (zh) 2013-11-01 2016-02-16 艾尼納製藥公司 ５－ＨＴｃ受體促效劑
CN116170766A (zh) 2013-11-07 2023-05-26 德克斯康公司 用于分析物值的发射和连续监测的系统和方法
US9610013B2 (en) 2013-11-14 2017-04-04 Dexcom, Inc. Indicator and analytics for sensor insertion in a continuous analyte monitoring system and related methods
EP3796332B1 (en) 2013-11-14 2025-08-06 Dexcom, Inc. Devices and methods for continuous analyte monitoring
EP3082574B1 (en) 2013-12-16 2023-07-12 Dexcom, Inc. Systems and methods for monitoring and managing life of a battery in an analyte sensor system worn by a user
PL3082484T3 (pl) 2013-12-19 2020-05-18 Philip Morris Products S.A. Układ wytwarzania aerozolu
EP2886153A1 (de) 2013-12-20 2015-06-24 LTS LOHMANN Therapie-Systeme AG System für die transdermale Abgabe von Wirkstoff
WO2015122964A1 (en) 2014-02-11 2015-08-20 Dexcom, Inc. Packaging system for analyte sensors
WO2015127558A1 (en) 2014-02-28 2015-09-03 UNIVERSITé LAVAL Methods and uses for inducing or facilitating micturition in a patient in need thereof
WO2015127556A1 (en) 2014-02-28 2015-09-03 UNIVERSITé LAVAL Methods and uses for inducing or facilitating defecation in a patient in need thereof
CN103816150A (zh) 2014-03-14 2014-05-28 兰州理工大学 山蚂蝗生物碱单体成分的用途
WO2015164541A1 (en) 2014-04-22 2015-10-29 Presage Biosciences, Inc. Methods and devices for evaluating drug candidates
EP3151906B1 (en) 2014-06-03 2019-12-11 Pop Test Abuse Deterrent Technology LLC Drug device configured for wireless communication
IL273507B2 (en) 2014-06-30 2024-06-01 Syqe Medical Ltd Methods, devices and systems for administering active substances through the lungs
US10202426B2 (en) 2014-07-30 2019-02-12 Genome Protection, Inc. Flagellin compositions and uses
US20170238851A1 (en) 2014-08-26 2017-08-24 Echo Therapeutics, Inc. Differential Biosensor System
US20160067711A1 (en) 2014-09-09 2016-03-10 The Regents Of The University Of Michigan Systems and methods for single cell isolation and analysis
AU2015318324A1 (en) 2014-09-17 2017-04-06 Mundipharma International Corporation Limited Crystalline forms of tyrosine kinase inhibitors and their salts
EP4418213A3 (en) 2014-10-06 2024-11-20 Dexcom, Inc. System and method for data analytics and visualization
MA41557A (fr) 2015-02-18 2017-12-26 Auspex Pharmaceuticals Inc Inhibiteurs diméthoxyphényles du transporteur vésiculaire des monoamines 2
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
CA2977885A1 (en) 2015-03-27 2016-10-06 Phillip Morris Products S.A. Aerosol-generating system comprising a rupturing portion
WO2016156212A1 (en) 2015-03-27 2016-10-06 Philip Morris Products S.A. Aerosol-generating system comprising integrated piercing element
ES2882588T3 (es) 2015-03-31 2021-12-02 Turtle Bear Holdings Llc Actividad antiviral de setas medicinales y sus constituyentes activos
CA2952818A1 (en) 2015-05-01 2016-11-10 Eran Eilat Compositions for the treatment of epistaxis
WO2016187277A1 (en) 2015-05-19 2016-11-24 Joseph Robert Knight Method for isolation of alkaloids and amino acids, and compositions containing isolated alkaloids and amino acids
US20180147142A1 (en) 2015-05-19 2018-05-31 Joseph Robert Knight Method for isolation of alkaloids and amino acids, and compositions containing isolated alkaloids and amino acids
WO2017044654A1 (en) 2015-09-10 2017-03-16 Dexcom, Inc. Transcutaneous analyte sensors and monitors, calibration thereof, and associated methods
WO2017044702A1 (en) 2015-09-11 2017-03-16 Pop Test LLC Therapeutic method and device
EP3394705A4 (en) 2015-12-21 2019-07-31 Dexcom, Inc. ENERGY SAVING IN A CONTINUOUS ANALYTICAL MONITORING SYSTEM
DE202016009211U1 (de) 2015-12-30 2024-04-08 Dexcom, Inc. Systeme für transkutane Analytsensoren
CZ307719B6 (cs) 2015-12-31 2019-03-20 Vysoká škola chemicko-technologická v Praze Použití derivátu tryptaminu
US20170210704A1 (en) 2016-01-21 2017-07-27 Enlibrium Inc Deutero-phenformin derivatives
US10668030B2 (en) 2016-04-21 2020-06-02 University Of Kentucky Research Foundation Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse
CA3021971A1 (en) 2016-04-26 2017-11-02 Ecolab Usa Inc. Corrosion inhibitor compositions and methods of using same
CA3017255C (en) 2016-05-02 2023-10-24 Dexcom, Inc. System and method for providing alerts optimized for a user
DE102016014603A1 (de) 2016-06-30 2018-01-04 Thomas Herkenroth Synthetisches Ayahuasca
US20180021326A1 (en) 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
US20210069170A1 (en) 2016-07-23 2021-03-11 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
CN109475296B (zh) 2016-08-12 2022-04-05 德克斯康公司 用于连续葡萄糖监测的健康数据可视化和用户支持工具的系统和方法
US20210137137A1 (en) 2016-08-21 2021-05-13 Insectergy, Llc Insect production systems and methods
US20200229411A1 (en) 2016-08-21 2020-07-23 Insectergy, Llc Insect production systems and methods
US11103499B2 (en) 2016-08-26 2021-08-31 EXCIVA (UG) (haftungsbeschränkt) Compositions and methods thereof
CA3075124C (en) 2016-09-09 2023-05-02 Dexcom, Inc. Systems and methods for cgm-based bolus calculator for display and for provision to medicament delivery devices
US10626105B2 (en) 2016-09-22 2020-04-21 Auspex Pharmaceuticals, Inc. Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
CN110049723B (zh) 2016-10-18 2022-10-11 德克斯康公司 分析物数据的通信系统和方法
US11295855B2 (en) 2016-11-09 2022-04-05 Dexcom, Inc. Systems and methods for technical support of continuous analyte monitoring and sensor systems
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
AU2017388066B9 (en) 2016-12-27 2021-04-01 Dexcom, Inc. Systems and methods for patient monitoring using an HCP - specific device
NL2018190B1 (en) 2017-01-18 2018-07-26 Procare Beheer B V Psilocybin or psilocin in combination with cannabinoid
JP7542311B2 (ja) 2017-01-19 2024-08-30 デックスコム・インコーポレーテッド 軟質検体センサ
EP3576755A4 (en) 2017-02-02 2020-12-02 McMaster University BICARBONATE AS A POTENTIALIZER OF ANTIMICROBIAL AGENTS
WO2018145219A1 (es) 2017-02-09 2018-08-16 Serani Mostazal Jorge Composición farmaceutica para la prevención y tratamiento de las adicciones a traves de un contracondicionamiento aversivo
CA3052974A1 (en) 2017-02-09 2018-08-16 CaaMTech, LLC Compositions and methods comprising a psilocybin derivative
US20190142851A1 (en) 2017-11-16 2019-05-16 CaaMTech, LLC Compositions comprising a psilocybin derivative and a cannabinoid
US11974984B2 (en) 2017-02-09 2024-05-07 Caamtech, Inc. Compositions and methods comprising a combination of serotonergic drugs
US20170173262A1 (en) 2017-03-01 2017-06-22 François Paul VELTZ Medical systems, devices and methods
CN108619214A (zh) 2017-03-15 2018-10-09 王慎君 一种治疗肿瘤的药物
US20200147038A1 (en) 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
CN110831584B (zh) 2017-05-04 2023-03-10 埃克塞瓦有限责任公司 具有新颖的组合物、组合的靶向药物拯救及其方法
WO2018204764A1 (en) 2017-05-05 2018-11-08 Camp4 Therapeutics Corporation Identification and targeted modulation of gene signaling networks
EP3634422A4 (en) 2017-05-11 2021-05-26 Ramot at Tel-Aviv University Ltd. METHOD FOR TREATMENT OF LEUCODYSTROPHIES
US20190246591A1 (en) 2017-05-31 2019-08-15 Insectergy, Llc Insect and cannabis production systems and methods
US11938119B2 (en) 2017-05-31 2024-03-26 Insectergy, Llc Cannabis production systems and methods
US20180343812A1 (en) 2017-05-31 2018-12-06 Insectergy, Llc Cannabis farming systems and methods
EP3629899A4 (en) 2017-06-02 2021-04-21 Northwestern University Thin, soft, skin-mounted microfluidic networks for detection and analysis of targets of interest in sweat
DK3928688T3 (da) 2017-06-23 2022-08-29 Dexcom Inc Transkunate analytsensorer, applikatorer dertil og kanylenav med antirotationselement
CN110997600A (zh) 2017-07-21 2020-04-10 佛罗里达州立大学研究基金会有限公司 光化学分离和组合物
WO2019021158A1 (en) 2017-07-23 2019-01-31 Pluristem Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF ADDICTIONS
WO2019058145A1 (en) 2017-09-25 2019-03-28 Small Pharma Ltd ORAL SOLID GALENIC FORMS OF KETAMINE DERIVATIVES
GB201715919D0 (en) 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
GB2588505B (en) 2017-10-09 2022-08-03 Compass Pathfinder Ltd Preparation of psilocybin
JP2021500948A (ja) 2017-10-19 2021-01-14 エレウシス ヘルス ソリューションズ ユーエス インコーポレイテッド サイケデリック薬剤療法の安全性を向上させる方法およびシステム
US11382540B2 (en) 2017-10-24 2022-07-12 Dexcom, Inc. Pre-connected analyte sensors
MA50786A (fr) 2017-10-26 2022-04-27 Blumentech S L Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
GB201717629D0 (en) 2017-10-26 2017-12-13 Univ Oxford Innovation Ltd Treatment of unipolar depressive disorder
EP3720506A4 (en) 2017-12-04 2021-09-29 Lecouteur, David COMPOSITIONS AND METHODS FOR MODULATING THE WINDOWS OF HEPATIC ENDOTHELIAL CELLS
FI128750B (en) 2017-12-21 2020-11-30 Helsingin Yliopisto Methods for determining the therapeutic effect of fast-acting antidepressants and related individual antidepressant therapy
WO2019161231A1 (en) 2018-02-16 2019-08-22 Botanical Process Solutions LLC Use of non-crystalline terpene alcohols for the inhibition of crystallization of cannabinoids
MX2020009254A (es) 2018-03-08 2021-01-15 New Atlas Biotechnologies Llc Procesos para la produccion de triptaminas.
WO2019213551A1 (en) 2018-05-04 2019-11-07 Perception Neuroscience, Inc. Methods of treating substance abuse
WO2019241451A1 (en) 2018-06-12 2019-12-19 University Of Washington Modified carbazoles as therapeutic agents
CA3148256A1 (en) 2018-06-21 2019-12-26 Robert John Petcavich Method of inducing dendritic and synaptic genesis in neurodegenerative chronic diseases
CN112822948A (zh) 2018-07-26 2021-05-18 应用生物学公司 用于治疗脱发的taar受体激动剂
EP3829640A4 (en) 2018-08-01 2022-05-25 McMaster University Methods for inhibiting microbe growth
WO2020024071A1 (es) 2018-08-03 2020-02-06 Universidad Del Desarrollo Composición farmacéutica para el tratamiento de la adicción a sustancias psicoactivas y/o para la prevención de las recaídas a dicha adicción
US12090145B2 (en) 2018-08-20 2024-09-17 Yale University Combination therapy for treating or preventing depression or other mood diseases
US11337937B2 (en) 2018-08-27 2022-05-24 ReJoy TARR receptor agonists for sexual dysfunction
CN108929259A (zh) 2018-08-29 2018-12-04 四川青木制药有限公司 一种制备赛洛多辛中间体的方法
WO2020053196A1 (en) 2018-09-10 2020-03-19 Universität Basel Method for the biocatalytic alkylation of a substrate
EP3626772A1 (en) 2018-09-19 2020-03-25 Borealis AG Use of a melamine based compound and a hals compound as heat stabilizer in polymers
US11672861B2 (en) 2018-10-15 2023-06-13 The George Washington University Prussian blue nanoparticles functionalized with immune signals and applications thereof
US11045454B2 (en) 2018-12-06 2021-06-29 Palo Alto Investors LP Methods of treating food allergy conditions
JP7502308B2 (ja) 2019-01-18 2024-06-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 固体投与形態を製造する方法および固体投与形態
MA54877A (fr) 2019-01-30 2021-12-08 Diamond Therapeutics Inc Compositions et méthodes comprenant un agoniste de récepteur 5ht destinées au traitement de troubles psychologiques, cognitifs, comportementaux et/ou d'humeur
HUE069534T2 (hu) 2019-02-22 2025-03-28 Gh Res Ireland Limited 5-Metoxi-N,N-dimetiltriptamint (5-MeO-DMT) tartalmazó készítmény mentális rendellenességek kezelésében történõ alkalmazásra
FI4349407T3 (fi) 2019-02-22 2025-06-02 Gh Res Ireland Limited 5-metoksi-n,n-dimetyylitryptamiini (5-meo-dmt) vaikean masennuksen hoitoon
KR102946120B1 (ko) 2019-02-27 2026-03-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클
MX2021010198A (es) 2019-02-27 2021-09-21 Univ California Indoles n-sustituidos y otros heterociclos para el tratamiento de trastornos cerebrales.
CA3132731A1 (en) 2019-03-07 2020-09-10 University Of Padova Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
WO2020185581A2 (en) 2019-03-08 2020-09-17 The Regents Of The University Of California Compositions and methods for modulating lipid and steroid metabolism
US12377112B2 (en) 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
EP3958755A4 (en) 2019-04-22 2023-01-04 Dexcom, Inc. PRE-CONNECTED ANALYTE SENSORS
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
WO2020247632A1 (en) 2019-06-04 2020-12-10 Waveform Technologies, Inc. Sensor signal processing with kalman-based calibration
CA3088384C (en) 2020-06-17 2021-08-03 Psilo Scientific Ltd. Extraction of psychoactive compounds from psilocybin fungus
US20220249512A1 (en) 2019-06-27 2022-08-11 S.L.A. Pharmca AG Topical pharmaceutical compositions comprising diltiazem
AU2020308897A1 (en) 2019-06-27 2022-01-27 Holobiome, Inc. Therapeutic compositions and methods of using serotonin modulating microbiome-based interventions to treat serotonin-related diseases or disorders
DE102019117739A1 (de) 2019-07-01 2021-01-07 Felix Blei Arylalkyamin-, Pyrrol-, Indol- und Opiatderivatkonzentrationsbestimmungsverfahren sowie Testkit unter Verwendung dieses Verfahrens
EP3994114A4 (en) 2019-07-04 2023-08-16 Canopy Growth Corporation CANNABINOID DERIVATIVES
WO2021000054A1 (en) 2019-07-04 2021-01-07 Canopy Growth Corporation Cannabinoid derivatives
US20220304980A1 (en) 2019-07-04 2022-09-29 SW Holdings, Inc Metered dosing compositions and methods of use of psychedelic compounds
WO2021007659A1 (en) 2019-07-12 2021-01-21 Canopy Growth Corporation Cannabinoid derivatives
JP2022540586A (ja) 2019-07-12 2022-09-16 キャノピー グロウス コーポレイション カンナビノイド誘導体
US12252503B2 (en) 2019-07-12 2025-03-18 Canopy Growth Corporation Cannabinoid derivatives
EP3997095B1 (en) 2019-07-12 2025-02-12 Canopy Growth Corporation Cannabinoid derivatives
WO2021007663A1 (en) 2019-07-12 2021-01-21 Canopy Growth Corporation Cannabinoid derivatives
WO2021009374A1 (fr) 2019-07-17 2021-01-21 Universite De Reims Champagne Ardenne Composes de type liquide ionique, leurs procedes de preparation et leurs utilisations
US20210015738A1 (en) 2019-07-17 2021-01-21 Concept Matrix Solutions Oral dissolvable film containing psychedelic compound
US11766445B2 (en) 2019-07-18 2023-09-26 Concept Matrix Solutions Oral soft gel capsule containing psychedelic compound
EP4003395A4 (en) 2019-07-23 2023-07-19 Caamtech, Inc. COMPOSITIONS WITH TOAD SECRETION COMPOUNDS
WO2021016710A1 (en) 2019-07-30 2021-02-04 Tassili Life Sciences, Corp. Controlled release formulations of multiple active pharmaceutical agents, and psilocybe-derived agents in combination with cannabis-derived agents and methods for their use
US20210030787A1 (en) 2019-07-31 2021-02-04 Applied Biology, Inc. Methods for protecting hair follicles
CN112430187B (zh) 2019-08-07 2023-01-17 北京奇点势能科技有限公司 一种α,β-氘代胺类化合物、氘代药物及其制备方法
BR112022002723A2 (pt) 2019-08-13 2022-07-19 Univ Maryland Métodos de tratamento de transtornos psicológicos e do cérebro
EP4017859A4 (en) 2019-08-25 2023-08-23 Caamtech, LLC ALKYL QUARTERNARY AMMONIUM TRYPTAMINE AND THEIR THERAPEUTIC USES
KR20220053015A (ko) 2019-08-30 2022-04-28 탈린 유니버시티 오브 테크놀로지 금지물질의 결정 장치 및 방법
AU2020351033A1 (en) 2019-09-16 2022-04-07 Danmarks Tekniske Universitet Yeast cells and methods for production of tryptophan derivatives
US11266314B2 (en) 2019-10-01 2022-03-08 Endra Life Sciences Inc. Method and system for determining a material type of an object of interest
CA3152752A1 (en) 2019-10-01 2021-04-08 Thomas Henley Genetic engineering of fungi to modulate tryptamine expression
WO2021062557A1 (en) 2019-10-02 2021-04-08 Canopy Growth Corporation Cannabinoid derivatives
JP2022551066A (ja) 2019-10-02 2022-12-07 キャノピー グロウス コーポレイション カンナビノイド誘導体
WO2021076572A1 (en) 2019-10-14 2021-04-22 The Regents Of The University Of California Ergoline-like compounds for promoting neural plasticity
WO2021072530A1 (en) 2019-10-15 2021-04-22 Tassili Life Sciences, Corp. Controlled release formulations of psilocybe-derived agents and method for their use, and methods and compositions for threating mild traumatic brain injury with post traumatic stress disorder.
US20210113644A1 (en) 2019-10-16 2021-04-22 Caamtech Llc Compositions containing kratom compounds
US20210114973A1 (en) 2019-10-18 2021-04-22 First Wave Bio, Inc. Pharmaceutical formulations
CA3158415A1 (en) 2019-10-21 2021-04-29 Esolate Ltd Compositions comprising superfine compounds and production thereof
AU2020374768B2 (en) 2019-10-28 2026-02-26 Miami University Methods for the production of psilocybin and intermediates or side products
US11246860B2 (en) 2019-11-07 2022-02-15 Lophora ApS 5-HT2A agonists for use in treatment of depression
KR20220082092A (ko) 2019-11-07 2022-06-16 스몰 파마 엘티디 화합물
WO2021097452A2 (en) 2019-11-15 2021-05-20 Cb Therapeutics, Inc. Biosynthetic production of psilocybin and related intermediates in recombinant organisms
AU2020386445B2 (en) 2019-11-19 2025-12-18 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
EP4065568A4 (en) 2019-11-26 2024-01-03 Canopy Growth Corporation CANNABINOIDS DERIVATIVES
WO2021102567A1 (en) 2019-11-26 2021-06-03 Canopy Growth Corporation Cannabigerol derivatives and use thereof as cannabinoid receptor modulators
US20230286906A1 (en) 2019-11-26 2023-09-14 Canopy Growth Corporation Cannabinoid derivatives
CA3160793A1 (en) 2019-12-04 2021-06-10 Neonmind Biosciences Inc. Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder
EP4073053A4 (en) 2019-12-09 2023-11-22 Canopy Growth Corporation CANNABINOID DERIVATIVES
WO2021113958A1 (en) 2019-12-09 2021-06-17 Canopy Growth Corporation Cannabinoid derivatives
EP4072590A4 (en) 2019-12-13 2024-01-03 Folium Labs Inc. COMPLEXES COMPRISING A CARBOHYDRATE POLYMER AND AN ACTIVE INGREDIENT AND THEIR PREPARATION PROCESSES
WO2021138564A1 (en) 2019-12-31 2021-07-08 Cure Pharmaceutical Holding Corp. Oral dissolvable film and method of manufacturing and using the same
US20230102999A1 (en) 2020-01-10 2023-03-30 First Wave Bio, Inc. Deuterated niclosamide
KR20220137081A (ko) 2020-02-04 2022-10-11 마인드셋 파마 인크. Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체
BR112022015379A2 (pt) 2020-02-04 2022-09-27 Mindset Pharma Inc Derivados de 3-pirrolidino-indol como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc
CA3166785A1 (en) 2020-02-05 2021-08-12 Yale University Psychedelic treatment for headache disorders
WO2021159213A1 (en) 2020-02-12 2021-08-19 Neonmind Biosciences Inc. Method for producing an extract of mushroom and mushroom extract made therefrom
KR20260008838A (ko) 2020-02-18 2026-01-16 길가메쉬 파마슈티컬스, 인코포레이티드 기분 장애 치료에 사용되기 위한 특이적 트립타민
US11780808B2 (en) 2020-02-27 2023-10-10 Caamtech, Inc. Crystalline bis-miprocin fumarate
US20210267985A1 (en) 2020-02-27 2021-09-02 Gerald Horn Compositions and methods for inducing enhanced brain function
WO2021178579A1 (en) 2020-03-03 2021-09-10 Alte Verde Llc Cannabis treatment of insomnia, pain, and skin conditions
US11801278B2 (en) 2020-03-05 2023-10-31 Cure Pharmaceutical, Inc. Method for obtaining an extract of a plant biomass
US20230162851A1 (en) 2020-03-09 2023-05-25 Eleusis Health Solutions Us, Inc. Methods and systems for enhancing clinical safety of psychoactive therapies
US20230140635A1 (en) 2020-03-12 2023-05-04 Bright Minds Biosciences Inc. 3-(2-(Aminoethyl)-Indol-4-ol Derivatives, Methods of Preparation Thereof, and the Use as 5-HT2 Receptor Modulators
US11753375B2 (en) 2020-03-19 2023-09-12 Caamtech, Inc. Crystalline psilacetin derivatives
AU2021237646B2 (en) 2020-03-19 2023-05-11 Caamtech, Inc. Crystalline norpsilocin compounds
WO2021188870A1 (en) 2020-03-20 2021-09-23 Orthogonal Thinker, Inc. Psilocybin and psilocin containing compositions and methods of using and making the same
US11332441B2 (en) 2020-03-23 2022-05-17 Caamtech, Inc. Crystalline N-methyl tryptamine derivatives
US11358934B2 (en) 2020-03-23 2022-06-14 Caamtech, Inc. Crystalline forms of psilacetin
EP4125978A4 (en) 2020-04-03 2024-06-05 Turtle Bear Holdings, LLC COMPOSITIONS AND METHODS FOR MODULATING THE INFLAMMATORY RESPONSE
EP4132527A4 (en) 2020-04-07 2024-04-24 Caamtech, Inc. CRYSTALLINE 5-METHOXY-N,N-DIALLYLTRYPTAMINE COMPOUNDS
MX2022012537A (es) 2020-04-16 2022-11-07 Pike Therapeutics Inc Entrega transdermica de microdosis de derivados psicodelicos.
EP4135713A4 (en) 2020-04-17 2024-04-17 Revive Therapeutics Ltd. Use of psilocybin in the treatment of neurological brain injury and migraines
US20210322306A1 (en) 2020-04-21 2021-10-21 Cure Pharmaceutical Holding Corp. Oral dissolvable film with high load of polymeric binder
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
WO2021234608A1 (en) 2020-05-19 2021-11-25 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
EP3902541B1 (en) 2020-06-02 2022-09-14 Small Pharma Ltd Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
CN116348448A (zh) 2020-07-24 2023-06-27 明德赛特制药公司 赛洛辛和赛洛西宾的可扩展合成路线
WO2022023812A1 (en) 2020-07-29 2022-02-03 Diamond Therapeutics Inc. Extended release 5-ht receptor agonists for neurological conditions
AU2021328671A1 (en) 2020-08-18 2023-02-16 Cybin Irl Limited Phenethylamine derivatives, compositions, and methods of use
JP7422474B2 (ja) 2020-08-28 2024-01-26 サイビン ユーケー リミテッド 注射用製剤
US20220062237A1 (en) 2020-08-28 2022-03-03 Small Pharma Ltd Injectable formulation
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
EP4221682A2 (en) 2020-10-02 2023-08-09 Cybin IRL Limited Methods for delivery of psychedelic medications by inhalation and systems for performing the methods
US11000534B1 (en) 2020-10-08 2021-05-11 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof
US11324762B2 (en) 2020-10-08 2022-05-10 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof
AU2021373520A1 (en) 2020-11-06 2023-06-29 Mynd Life Sciences Inc. A method of treating depression by immune modulation
EP4031529B1 (en) 2020-12-01 2023-09-27 Small Pharma Ltd Deuterated or partially deuterated n,n-dimethyltryptamine compounds
JP2024506383A (ja) 2021-02-10 2024-02-13 エレウシス セラピューティクス ユーエス，インコーポレーテッド シロシンの薬学的に許容可能な塩及びその使用
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
AU2022229037A1 (en) 2021-03-02 2023-09-28 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
US20220370413A1 (en) 2021-03-06 2022-11-24 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
US20220280482A1 (en) 2021-03-06 2022-09-08 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
WO2022195011A1 (en) * 2021-03-18 2022-09-22 Cybin Irl Limited Psilocybin analogs, salts, compositions, and methods of use
WO2022225884A1 (en) 2021-04-22 2022-10-27 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psychedelic compounds and uses thereof
CA3218110A1 (en) 2021-05-25 2022-12-01 Majed Fawaz New n,n-dimethyltryptamine salts and crystalline salt forms
BR112023024688A2 (pt) 2021-05-26 2024-02-15 Mindset Pharma Inc Combinação de halucinógeno-ácido graxo
JP2024533291A (ja) 2021-09-08 2024-09-12 サイビン アイアールエル リミテッド 併用薬物療法
WO2023076135A1 (en) 2021-10-29 2023-05-04 Psilera Inc. N,n-dimethyltryptamine (dmt) crystalline products and methods of making the same
EP4433049A1 (en) 2021-11-18 2024-09-25 Cybin UK Ltd Injectable and inhalable formulations
WO2023107931A1 (en) 2021-12-06 2023-06-15 Terran Biosciences, Inc. Salt and solid forms of indole analogs and methods of use thereof

Also Published As

Publication number Publication date
US20230066286A1 (en) 2023-03-02
US20250011282A1 (en) 2025-01-09
KR20240096817A (ko) 2024-06-26
US20230202979A1 (en) 2023-06-29
JP2026048628A (ja) 2026-03-17
US20230126298A1 (en) 2023-04-27
EP4397371A2 (en) 2024-07-10
US12291499B2 (en) 2025-05-06
CN115667217A (zh) 2023-01-31
IL297492A (en) 2022-12-01
IL312785B1 (en) 2026-02-01
JP7770467B2 (ja) 2025-11-14
JP2024119821A (ja) 2024-09-03
CN118754841A (zh) 2024-10-11
US20230357147A1 (en) 2023-11-09
PH12022553135A1 (en) 2024-03-04
US11746088B2 (en) 2023-09-05
IL325449A (en) 2026-02-01
US20230219889A1 (en) 2023-07-13
US20250230128A1 (en) 2025-07-17
EP4153564A1 (en) 2023-03-29
US20220119346A1 (en) 2022-04-21
CA3177454A1 (en) 2021-11-25
US11958807B2 (en) 2024-04-16
EP4153564A4 (en) 2024-06-19
US20240270691A1 (en) 2024-08-15
CO2022016662A2 (es) 2022-11-29
EP4397371A3 (en) 2024-10-30
US20250154101A1 (en) 2025-05-15
JP2023526856A (ja) 2023-06-23
US11834410B2 (en) 2023-12-05
US12240813B2 (en) 2025-03-04
JP2026031961A (ja) 2026-02-25
US11724985B2 (en) 2023-08-15
JP7766623B2 (ja) 2025-11-10
US20240067605A1 (en) 2024-02-29
US12110272B2 (en) 2024-10-08
IL312785A (en) 2024-07-01
AU2021276656A1 (en) 2022-11-24
KR20230012501A (ko) 2023-01-26
US11242318B2 (en) 2022-02-08
US20210363104A1 (en) 2021-11-25
AU2024203974A1 (en) 2024-07-04

Similar Documents

Publication Publication Date Title
MX2024006467A (es) Derivados de triptamina deuterada y metodos de uso.
MX2022014605A (es) Derivados de triptamina deuterada y metodos de uso.
MX2021001690A (es) Indoles sustituidos y metodos de uso de los mismos.
MX2023013584A (es) Formas cristalinas de un inhibidor de tlr7/tlr8.
MX2020009929A (es) Compuestos organicos.
PE20070093A1 (es) Derivados dihidrobenzofuranos como moduladores del receptor 5-ht2c
CL2023002731A1 (es) Análogos, sales, composiciones y métodos de uso de la psilocibina
ECSP055684A (es) Antagonistas del receptor opiode
NO20052728D0 (no) Substituerte tricykliske gamma-karboliner som serotonin reseptor agonister og antagonister
UA107080C2 (uk) Сполуки n-феніл(піперазиніл або гомопіперазиніл)бензолсульфонаміду або бензолсульфонілфеніл(піперазину або гомопіперазину), придатні для лікування захворювань, які реагують на модулювання рецептора 5-ht6 серотоніну
PE20081368A1 (es) Derivados de azabiciclo[4.1.0]heptano como inhibidores de la recaptacion de serotonina, dopamina y norepinefrina
MX2024011170A (es) Compuestos organicos.
PE20121049A1 (es) Derivados de pirazinooxazepina
EA200801001A1 (ru) Соединения, которые обладают активностью по отношению к рецепторам м, и их применения в медицине
WO2024054866A3 (en) Heteroatom substituted cyclic and alkyl amines as activators of serotonin receptors
EA202190323A1 (ru) ИМИДАЗО[1,2-b]ПИРИДАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk
PE20080941A1 (es) Compuestos triciclicos como agonistas del receptor de melatonina
PE20000413A1 (es) Ligandos azabiciclicos de receptores 5ht1
CY1112638T1 (el) Χρηση των παραγωγων ινδολιου ως ενεργοποιητες νurr-1 για την θεραπεια νοσου ραrκινsον
PE20040928A1 (es) Derivados de tetrahidroquinolinas como moduladores del receptor fsh
PH12022550627A1 (en) ESTROGEN-RELATED RECEPTOR ALPHA (ERRa) MODULATORS
PE108498A1 (es) Ligandos espirociclicos de un subtipo de receptor de la dopamina
MX381768B (es) Combinación de antagonistas puros del receptor 5-ht6 con inhibidores de la acetilcolinesterasa.
PE20040659A1 (es) Derivados de 3-guanidinocarbonil-1-heteroaril-indol, procedimiento de preparacion y composiciones farmaceuticas que los comprenden
PE20060632A1 (es) Derivados de arilsulfonilestilbeno como antagonistas de los receptores 5-ht2a